country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-100897

Copy Link Print Information

Sulodexide

カスタマーレビュー

Based on 1 Customer Validation

Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease. Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 57821-29-1

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Sulodexide 構造式

CAS 番号: 57821-29-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Sulodexide is a mixture of glycosaminoglycans available in soft capsule form for oral administration. It is composed of low molecular weight heparin (80%) and dermatan sulfate (20%). Sulodexide exhibits antithrombotic activity through interaction with antithrombin III (AT III) and heparin cofactor II (HC II), and inhibition of thrombin formation. Sulodexide exhibits profibrinolytic activity through release of tissue plasminogen activator (tPA). Sulodexide exhibits endothelial protective and anti-inflammatory effect, ameliorates chronic venous disease^[1]. Sulodexide is a glycosaminoglycan mixture available in soft gelatin capsule form for oral administration.

体外実験

Sulodexide (0–200 μg/mL, 24 hours) promotes fibronectin and collagen type III synthesis in mouse mesangial cells^[2].
Sulodexide (50 µg/mL, 48 hours) significantly inhibits capillarization marker expression in LSECs^[4].
Note: This product is in soft capsule form and has viscous contents.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

Mouse mesangial cells (diabetic nephropathy)
Concentration:

0–200 μg/mL
Incubation Time:

24 hours
Result:

Increased synthesis of fibronectin and collagen type III in cells, further enhanced under high glucose conditions.

Real Time qPCR^[4]

Cell Line:

Mouse liver sinusoidal endothelial cells (LSECs; liver fibrosis)
Concentration:

50 µg/mL
Incubation Time:

48 hours
Result:

Significantly reduced expression of capillarization markers Edn1 and CD34.

体内実験

Sulodexide (1 mg/kg, p.o., once daily for 12 weeks) significantly improves proteinuria and renal function in Streptozotocin (HY-13753)-induced type I diabetic nephropathy in mice^[2].
Sulodexide (5 mg/kg and 15 mg/kg, i.p., once daily for 5 days) significantly inhibits retinal neovascularization and suppressed pro-angiogenic protein expression in the oxygen-induced retinopathy model in ICR mice^[3].
Sulodexide (20 mg/kg, i.g., once daily for 4 weeks) significantly attenuats fibrosis in the Thioacetamide (HY-Y0698)-induced liver fibrosis model in mice^[4].
Sulodexide (40 mg/kg, i.g., single dose) significantly improvs survival and reduced lung injury in the LPS (HY-D1056)-induced endotoxemia model in C57BL/6J mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Streptozotocin (HY-13753)-induced type I diabetic nephropathy in C57BL/6 mice model^[2]
Dosage:

1 mg/kg
Administration:

Oral gavage (p.o.), once daily for 12 weeks
Result:

Significantly reduced urinary albumin levels, improved renal function, increased GBM perlecan expression, reduced collagen I and IV deposition, and ERK activation.

Animal Model:

Oxygen-induced retinopathy (OIR) model in ICR mice^[3]
Dosage:

5 mg/kg and 15 mg/kg
Administration:

Intraperitoneal injection (i.p.), once daily for 5 days
Result:

Significantly reduced avascular area, decreased neovascular tufts and lumens.
Significantly inhibited expression of MMP-2, MMP-9, and VEGF

Animal Model:

Thioacetamide (HY-Y0698)-induced liver fibrosis in C57BL/6 mice model^[4]
Dosage:

20 mg/kg
Administration:

Intragastric administration (i.g.), once daily for 4 weeks
Result:

Significantly reduced expression of fibrosis markers (Col1a1 and α-SMA), decreased hydroxyproline levels, and inhibited ECM deposition in liver tissue.

Animal Model:

LPS (HY-D1056)-induced endotoxemia in C57BL/6J mice model^[5]
Dosage:

40 mg/kg
Administration:

Intragastric administration (i.g.), single dose
Result:

Significantly reduced plasma Syndecan-1 (SDC1) levels, increased survival rate, reduced lung injury, and restored endothelial glycocalyx damage.

化学情報

CAS 番号 57821-29-1
性状 Solid-Liquid Mixture
Color Colorless to light yellow
SMILES

[Sulodexide]
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

溶剤 & 溶解度

体外:

DMSO : < 1 mg/mL (insoluble or slightly soluble)

Ethanol : < 1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012 Apr 1;12(2):73-81. [Content Brief]

[2]. Yung S, et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy[J]. PloS one, 2013, 8(1): e54501. [Content Brief]

[3]. Jo H, et al. Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy[J]. BMB reports, 2014, 47(11): 637. [Content Brief]

[4]. Huang R, et al. Sulodexide attenuates liver fibrosis in mice by restoration of differentiated liver sinusoidal endothelial cell[J]. Biomedicine & Pharmacotherapy, 2023, 160: 114396. [Content Brief]

[5]. Ying J, et al. Sulodexide improves vascular permeability via glycocalyx remodelling in endothelial cells during sepsis[J]. Frontiers in immunology, 2023, 14: 1172892. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ